Adherex Technologies (FENC) had its "outperform" rating reaffirmed by Wedbush. They now have a $13.00 price target on the stock.
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adherex Technologies (FENC) was downgraded by Zacks Research from "hold" to "strong sell".